Bufalin enhances ABT-737 efficacy through Mcl-1 degradation in non-small cell lung cancer cells

Wen-yu Di; Wen-yu Di; Guang-jian Lu; Guang-jian Lu; Bao-cai Lu; Bao-cai Lu; Li-na Wang; Li-na Wang; Jing-hang Zhang; Jing-hang Zhang; Jian Yu; Jian Yu; Wei Su; Wei Su; Xiao-hong Kang; Xiao-hong Kang; Ping Lu; Ping Lu

doi:10.18632/oncotarget.23600

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 12/22/2017.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Research Papers:

Bufalin enhances ABT-737 efficacy through Mcl-1 degradation in non-small cell lung cancer cells

Wen-yu Di, Wen-yu Di, Guang-jian Lu, Guang-jian Lu, Bao-cai Lu, Bao-cai Lu, Li-na Wang, Li-na Wang, Jing-hang Zhang, Jing-hang Zhang, Jian Yu, Jian Yu, Wei Su, Wei Su, Xiao-hong Kang _, Xiao-hong Kang, Ping Lu and Ping Lu _

Wen-yu Di1, Guang-jian Lu2, Bao-cai Lu3, Li-na Wang4, Jing-hang Zhang1, Jian Yu1, Wei Su1, Xiao-hong Kang5,*and Ping Lu5,*

1 Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China

2 Department of Laboratory, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, 453003, China

3 Department of ENT, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, 453003, China

4 Quality Controlling Office, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, 453003, China

5 Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, 453003, China

* These authors have contributed equally

Correspondence:

Xiao-hong Kang, email: [email protected]

Ping Lu, email: [email protected]

Keywords: bualin; ABT-737; Mcl-1; non-small cell lung cancer; GSK-3β; Ku70

Received: August 21, 2017 Accepted: December 04, 2017 Epub: December 22, 2017

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23600

Publication Alerts

Withdrawal Notice

Research Papers:

Bufalin enhances ABT-737 efficacy through Mcl-1 degradation in non-small cell lung cancer cells